BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/27/2025 8:08:15 AM | Browse: 195 | Download: 294
 |
Received |
|
2025-07-23 02:03 |
|
Peer-Review Started |
|
2025-07-23 02:04 |
|
First Decision by Editorial Office Director |
|
2025-08-25 07:52 |
|
Return for Revision |
|
2025-08-25 07:52 |
|
Revised |
|
2025-08-25 14:05 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-09-30 02:46 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-30 06:31 |
|
Articles in Press |
|
2025-09-30 06:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-10-21 01:46 |
|
Publish the Manuscript Online |
|
2025-10-27 08:08 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Vasily Isakov and Alexei Goncharov |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Science and Higher Education of the Russian Federation |
FGMF-2025-0003 |
|
| Corresponding Author |
Vasily Isakov, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, 21 Kashirskoe Shosse, Moscow 115446, Russia. vasily.isakov@gmail.com |
| Key Words |
Helicobacter pylori; First-line treatment; Vonoprazan; Triple therapy; Proton pump inhibitors |
| Core Tip |
This editorial highlights a pivotal multicenter randomized controlled trial from China demonstrating that vonoprazan (VPZ)-based triple therapy achieves superior or non-inferior Helicobacter pylori eradication rates compared to standard bismuth quadruple regimens, even in high clarithromycin resistance regions. The 10-day VPZ-amoxicillin-clarithromycin regimen exceeded 90% per-protocol efficacy with fewer adverse events, offering a simplified, well-tolerated alternative aligned with global treatment goals. These findings underscore a shift in empirical first-line therapy and support the integration of VPZ into updated regional and international guidelines. |
| Publish Date |
2025-10-27 08:08 |
| Citation |
Isakov V, Goncharov A. Breaking barriers in the first-line Helicobacter pylori treatment: Chinese multicenter trial validates vonoprazan-based triple therapy. World J Gastroenterol 2025; 31(40): 112312 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i40/112312.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i40.112312 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
